Ruifu Chemical Supply Intermediates of Afatinib
Afatinib CAS 439081-18-2
Afatinib Dimaleate CAS 850140-73-7
(S)-(+)-3-Hydroxytetrahydrofuran CAS 86087-23-2
(Dimethylamino)acetaldehyde Diethyl Acetal CAS 3616-56-6
trans-4-Dimethylaminocrotonic Acid Hydrochloride CAS 848133-35-7
Diethylphosphonoacetic Acid CAS 3095-95-2
7-Fluoro-6-Nitroquinazolin-4(1H)-one CAS 162012-69-3
7-Chloro-6-Nitro-4-Hydroxyquinazoline CAS 53449-14-2
N-(3-Chloro-4-Fluorophenyl)-7-Fluoro-6-Nitroquinazolin-4-Amine CAS 162012-67-1
(S)-N4-(3-Chloro-4-Fluorophenyl)-7-((Tetrahydrofuran-3-yl)oxy)quinazoline-4,6-Diamine CAS 314771-76-1
(S)-N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl)oxy)quinazolin-4-Amine CAS 314771-88-5
| Chemical Name |
(S)-N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl)oxy)quinazolin-4-Amine |
| Synonyms |
N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-[(3S)-oxolan-3-yl]oxyquinazolin-4-Amine; 7-((S)-Tetrahydrofuran-3-yloxy)-4-(3-Chloro-4-Fluorophenyl)amino-6-Nitroquinazoline; Afatinib Impurity |
| CAS Number |
314771-88-5 |
| CAT Number |
RF-PI2027 |
| Stock Status |
In Stock, Production Scale Up to Tons |
| Molecular Formula |
C18H14ClFN4O4 |
| Molecular Weight |
404.78 |
| Density |
1.534±0.060 g/cm3 |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
Yellow to Light Yellow Powder |
| Purity / Analysis Method |
>99.0% (HPLC) |
| Loss on Drying |
<0.50% |
| Individual Impurity |
<0.50% |
| Total Impurities |
<1.00% |
| Heavy Metals |
≤20ppm |
| Test Standard |
Enterprise Standard |
| Usage |
Intermediate of Afatinib Dimaleate (CAS: 850140-73-7)
|
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture
(S)-N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl)oxy)quinazolin-4-Amine (CAS: 314771-88-5) is used in the preparation of Afatinib Dimaleate (CAS: 850140-73-7). Afatinib is an innovative anti-cancer target drug, a new generation of oral target drug, the world's first anti-cancer target drug that irreversibly binds to the ErbB family, and is more effective and targeted Blocks the signal that triggers the growth of cancer cells, reducing or delaying the proliferation of cancer cells. Afatinib belongs to a class of drugs known as tyrosine kinase inhibitors. It works by blocking the function of two closely related proteins, the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2). Used for the first-line treatment of patients with metastatic non-small cell lung cancer. Afatinib is an innovative anti-cancer target drug, a new generation of oral target drug, the world's first anti-cancer target drug that irreversibly binds to the ErbB family, and is more effective and targeted Blocks the signal that triggers the growth of cancer cells, reducing or delaying the proliferation of cancer cells.